A phase 2 trial of rilzabrutinib in IgG4-related disease.
- DOI
- 10.1016/j.ard.2026.05.017
- Published
- 2026 Jul 21
- Container
- Annals of the rheumatic diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ard.2026.05.017,
title = {A phase 2 trial of rilzabrutinib in IgG4-related disease.},
author = {Stone JH and Carruthers M and Baker MC and Meysami A and Spiera R and Ghetie D and Valle FM and Dagna L and Della-Torre E and Schleinitz N and Lally L and Wu T and Choi J and Mikol V and Yen K and Mannent L and Hagino O},
year = {2026},
journal = {Annals of the rheumatic diseases},
doi = {10.1016/j.ard.2026.05.017},
url = {https://doi.org/10.1016/j.ard.2026.05.017}
}RIS
TY - JOUR TI - A phase 2 trial of rilzabrutinib in IgG4-related disease. AU - Stone JH AU - Carruthers M AU - Baker MC AU - Meysami A AU - Spiera R AU - Ghetie D AU - Valle FM AU - Dagna L AU - Della-Torre E AU - Schleinitz N AU - Lally L AU - Wu T AU - Choi J AU - Mikol V AU - Yen K AU - Mannent L AU - Hagino O PY - 2026 JO - Annals of the rheumatic diseases DO - 10.1016/j.ard.2026.05.017 UR - https://doi.org/10.1016/j.ard.2026.05.017 ER -
APA
JH, S., M, C., MC, B., A, M., R, S., D, G., FM, V., L, D., E, D., N, S., L, L., T, W., J, C., V, M., K, Y., L, M., & O, H. (2026). A phase 2 trial of rilzabrutinib in IgG4-related disease.. Annals of the rheumatic diseases. https://doi.org/10.1016/j.ard.2026.05.017
Source records
- pubmed · retrieved 2026-09-26T17:54:47.749Z